 Mark A. Gregory
| Title | Asst Professor-Research |
|---|
| Institution | University of Colorado Denver - Anschutz Medical Campus |
|---|
| Department | SOM-BioChem&Molecular Genetics |
|---|
| Phone | 303/724-3233 |
|---|
|
|
|
 Research K22CA172757 (GREGORY, MARK A)Sep 15, 2012 - Aug 31, 2015 NIH
Targeting an ATM-dependent metabolic pathway and FLT3 for AML therapy
Role: Principal Investigator |
| K01CA133182 (GREGORY, MARK A)Jul 1, 2009 - Jun 30, 2012 NIH
Targeting Wnt/Ca2+ Pathway components and Bcr-Abl for the treatment of CML
Role: Principal Investigator |
Bibliographic
-
Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clin Cancer Res. 2019 07 01; 25(13):4079-4090. PMID: 30940653.
-
Gregory MA, Nemkov T, Reisz JA, Zaberezhnyy V, Hansen KC, D'Alessandro A, DeGregori J. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia. Exp Hematol. 2018 02; 58:52-58. PMID: 28947392.
-
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6669-E6678. PMID: 27791036.
-
Ahmed K, Gregory MA. Distributed efficient similarity search mechanism in wireless sensor networks. Sensors (Basel). 2015 Mar 05; 15(3):5474-503. PMID: 25751081.
-
Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015 Mar 15; 21(6):1360-72. PMID: 25547679.
-
Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903. PMID: 24891015.
-
Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4149-62. PMID: 23757356.
-
Alvarez-Calderon F, Gregory MA, DeGregori J. Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunol Res. 2013 Mar; 55(1-3):100-15. PMID: 22941562.
-
Zhang Q, Spears E, Boone DN, Li Z, Gregory MA, Hann SR. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. Proc Natl Acad Sci U S A. 2013 Jan 15; 110(3):978-83. PMID: 23277542.
-
Nifoussi SK, Vrana JA, Domina AM, De Biasio A, Gui J, Gregory MA, Hann SR, Craig RW. Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS One. 2012; 7(10):e47060. PMID: 23056582.
-
Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010 Jul 13; 18(1):74-87. PMID: 20609354.
-
Gregory MA, Qi Y, Hann SR. The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle. 2005 Feb; 4(2):249-52. PMID: 15655352.
-
Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature. 2004 Oct 07; 431(7009):712-7. PMID: 15361884.
-
Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004 Jul 08; 23(31):5301-15. PMID: 15241487.
-
Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003 Dec 19; 278(51):51606-12. PMID: 14563837.
-
Gregory MA, Xiao Q, Cornwall GA, Lutterbach B, Hann SR. B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation. Oncogene. 2000 Oct 05; 19(42):4886-95. PMID: 11039906.
-
Niklinski J, Claassen G, Meyers C, Gregory MA, Allegra CJ, Kaye FJ, Hann SR, Zajac-Kaye M. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma. Mol Cell Biol. 2000 Jul; 20(14):5276-84. PMID: 10866684.
-
Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol. 2000 Apr; 20(7):2423-35. PMID: 10713166.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2000 | 3 | | 2003 | 1 | | 2004 | 2 | | 2005 | 1 | | 2010 | 1 | | 2012 | 2 | | 2013 | 2 | | 2014 | 2 | | 2015 | 1 | | 2016 | 1 | | 2017 | 1 | | 2019 | 1 |
To return to the timeline, click here.
|
Gregory's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|